Disclaimer: I’m participating in the Break Up with Your Makeup program sponsored by Galderma Laboratories, L.P. the maker of Oracea® (doxycycline) 40 mg* Capsules, Soolantra® (ivermectin) Cream, 1% and Mirvaso® (brimonidine) Gel, 0.33%**.
I remember being a pre-teen and just dying to be able to wear makeup. Of course, my mom said no and told me I should be thankful to have the kind of skin most people try to mimic by wearing makeup. I didn’t see it that way and had no concept of what she meant.
Fast forward a number of years and I suddenly “get” what my mom had been trying to tell me. These days, I’d love to be able to leave the house with no makeup on! Sadly, that isn’t really an option for me as my very pale Irish skin looks very blotchy and red in areas thanks to rosacea. I generally feel pretty self-conscious unless I have at least one layer of tinted something on my face.
For the third year in a row, Galderma Laboratories, L.P. has launched the “Break Up with Your Makeup” campaign to help bring awareness to the fact that there are better solutions than just covering up rosacea – like actually treating it.
Rosacea is a chronic, inflammatory and vascular skin condition affecting the face.
Galderma has a number of prescription treatments for rosacea that could have you tossing your makeup aside and baring your bare face for the world to see without hesitation. Options include Soolantra® (ivermectin) Cream, 1%, Oracea® (doxycycline) 40 mg* Capsules, and Mirvaso® (brimonidine) Gel, 0.33%** – your dermatologist can give you more information on what prescription may be right for you.
Here is some additional information and even a cool giveaway to enter. If you share your own rosacea story, you could win a trip to LA!
Important Safety Information for Oracea® Capsules Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established. *30 mg immediate release & 10 mg delayed release beads Full Prescribing Information
Important Safety Information for Soolantra® Cream
Indication: SOOLANTRA® (ivermectin) Cream, 1%, is indicated for the treatment of inflammatory lesions of rosacea. Not for oral, ophthalmic or intravaginal use. Adverse Events: In clinical trials with SOOLANTRA® Cream, the most common adverse reactions (incidence ≤1%) included skin burning sensation and skin irritation.
Important Safety Information for Mirvaso® Gel
Indication: Mirvaso® (brimonidine) topical gel, 0.33%** is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
**Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
All trademarks are the property of their respective owners.